Neuroinflammation Pathway

Neuroinflammation Pathway

The neuroinflammation pathway is a central mechanism in neurodegenerative diseases, involving the coordinated activation of innate immune cells in the brain in response to pathological insults. While acute neuroinflammation serves a protective role, chronic neuroinflammation contributes to neuronal dysfunction and death.

Overview

Neuroinflammation is initiated by:

• DAMPs (Damage-Associated Molecular Patterns) — ATP, HMGB1, nucleic acids released from damaged [neurons](/entities/neurons)
• PAMPs (Pathogen-Associated Molecular Patterns) — viral/bacterial components in rare infectious triggers
• Endogenous misfolded proteins — [Aβ](/proteins/amyloid-beta), [tau](/proteins/tau), [α-synuclein](/proteins/alpha-synuclein) aggregates acting as danger signals

These triggers activate pattern recognition receptors (PRRs) on [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), triggering a signaling cascade that produces pro-inflammatory cytokines, chemokines, and reactive oxygen/nitrogen species[@ransohoff2016].

Signaling Cascade

...

Neuroinflammation Pathway

The neuroinflammation pathway is a central mechanism in neurodegenerative diseases, involving the coordinated activation of innate immune cells in the brain in response to pathological insults. While acute neuroinflammation serves a protective role, chronic neuroinflammation contributes to neuronal dysfunction and death.

Overview

Neuroinflammation is initiated by:

• DAMPs (Damage-Associated Molecular Patterns) — ATP, HMGB1, nucleic acids released from damaged [neurons](/entities/neurons)
• PAMPs (Pathogen-Associated Molecular Patterns) — viral/bacterial components in rare infectious triggers
• Endogenous misfolded proteins — [Aβ](/proteins/amyloid-beta), [tau](/proteins/tau), [α-synuclein](/proteins/alpha-synuclein) aggregates acting as danger signals

These triggers activate pattern recognition receptors (PRRs) on [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), triggering a signaling cascade that produces pro-inflammatory cytokines, chemokines, and reactive oxygen/nitrogen species[@ransohoff2016].

Signaling Cascade

Key Players

Pattern Recognition Receptors

| Receptor | Ligands | Signaling Adapters | Disease Relevance |
|----------|---------|-------------------|-------------------|
| TLR4 | Aβ, HMGB1, LPS | MyD88, TRIF | AD, PD [@zhang2013] |
| TLR9 | DNA, Aβ aggregates | MyD88 | AD, MS |
| RAGE | Aβ, HMGB1, S100 | NF-κB, MAPK | AD, PD, ALS [@lyman2014] |
| NLRP3 | Aβ, MSU, ATP | ASC, caspase-1 | AD, PD [@zhou2011] |

Pro-inflammatory Cytokines

| Cytokine | Source Cells | Primary Effects | Therapeutic Target |
|----------|--------------|------------------|-------------------|
| TNF-α | Microglia, astrocytes | Neuronal apoptosis | Etanercept, Infliximab |
| IL-1β | Microglia, monocytes | Tau phosphorylation [@kitazawa2005] | Anakinra, Canakinumab |
| IL-6 | Microglia, astrocytes | Acute phase response | Tocilizumab |
| IL-18 | Microglia, macrophages | IFN-γ induction | Not tested |

Microglial Polarization: M1 vs M2

Microglia can adopt distinct activation states:

M1 (Classical Activation)

• Triggered by: IFN-γ, LPS, Aβ, TNF-α
• Markers: CD16, CD32, CD86, iNOS
• Function: Pro-inflammatory, cytotoxic

M2 (Alternative Activation)

• Triggered by: IL-4, IL-13, IL-10, glucocorticoids
• Markers: CD206, Arg1, YM1, Fizz1
• Function: Anti-inflammatory, tissue repair

Disease-Associated Microglia (DAM)

Microglia adopt disease-specific phenotypes[@kerenshaul2017]:

Stage 1 DAM:

• [TREM2](/proteins/trem2-protein)-independent
• Downregulation of homeostatic genes
• Upregulation of immune genes

Stage 2 DAM:

• [TREM2](/genes/trem2)-dependent
• Phagocytic genes upregulated
• Lipid metabolism genes activated

Role in Specific Diseases

Alzheimer's Disease

Neuroinflammation is both a consequence and driver of AD pathology:

Aβ activates microglia via [TLR4](/entities/tlr4) and [NLRP3 inflammasome](/entities/nlrp3-inflammasome)[@halle2008]

IL-1β promotes [tau](/proteins/tau) phosphorylation via [CDK5](/proteins/cdk5-protein) and GSK3β

TNF-α enhances Aβ production through [BACE1](/entities/bace1) upregulation

Complement activation (C1q, C3) drives synaptic pruning

TREM2 variants (R47H, R62H) increase AD risk ~3x[@guerreiro2013]

Parkinson's Disease

α-Synuclein aggregates activate microglia via TLR2/TLR4

NLRP3 inflammasome is activated in PD substantia nigra[@fan2015]

Pro-inflammatory cytokines contribute to dopaminergic neuron death

Amyotrophic Lateral Sclerosis

Activated microglia surround motor neurons in ALS

NLRP3 and ASC specks are found in ALS spinal cord

[C9orf72](/entities/c9orf72) mutations cause innate immune dysregulation

Genetic Risk Factors

| Gene | Variant | Effect on Neuroinflammation | Disease |
|------|---------|----------------------------|---------|
| TREM2 | R47H, R62H | Loss of phagocytic function | AD |
| CD33 | rs3865444 | Increased expression | AD |
| CR1 | rs6653641 | Altered complement | AD |
| INPP5D | rs35349669 | Altered signaling | AD |

Therapeutic Targets

Anti-inflammatory Drug Strategies

| Target | Drug Class | Examples | Stage |
|--------|-----------|----------|-------|
| TNF-α | Monoclonal antibodies | Etanercept | Phase II |
| IL-1β | IL-1Ra | Anakinra | Phase II |
| NLRP3 | Inhibitors | MCC950 | Preclinical |
| COX-2 | NSAIDs | Celecoxib | Failed |

Microglial Modulation

• TREM2 agonists — enhance phagocytosis
• CD33 blockade — reduce activation
• PPAR-γ agonists — shift phenotype

Biomarkers

CSF Biomarkers

| Biomarker | Change in Disease |
|-----------|------------------|
| IL-1β | Increased in AD, PD |
| IL-6 | Increased in AD |
| TNF-α | Increased in AD, PD |
| YKL-40 | Marker of gliosis |

PET Imaging

• TSPO PET: Measures microglial activation[@varley2015]

Neuroinflammation and Synaptic Dysfunction

Chronic neuroinflammation directly damages synapses[@stevens2008]:

• Complement-mediated pruning: C1q and C3 tag synapses
• Microglial phagocytosis: Engulfment of synaptic material
• Cytokine toxicity: Direct effects on synaptic proteins
• Oxidative stress: Damage to synaptic membranes

Aging and Neuroinflammation

• Microglial dystrophy: Age-related changes
• Inflammaging: Chronic low-grade inflammation
• Microglial priming: Enhanced inflammatory response
• Reduced clearance: Declining phagocytic capacity

Cross-Linking to Other Mechanisms

• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway) — Aβ activates microglia
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway) — Cytokines promote tau pathology
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway) — [ROS](/entities/reactive-oxygen-species) from microglia

Microglia-Astrocyte Cross-Talk in Neuroinflammation

Bidirectional Signaling Networks

Microglia and astrocytes engage in extensive bidirectional communication that shapes the neuroinflammatory landscape in neurodegenerative diseases. This cross-talk operates through multiple signaling pathways that amplify or suppress inflammatory responses depending on the disease context and stage.

Key Crosstalk Mechanisms

Cytokine-Mediated Communication:

IL-1β Signaling: Activated microglia release IL-1β, which potently induces astrocyte reactivity and A1 neurotoxic phenotype formation. IL-1β signaling through IL-1R1 on astrocytes triggers NF-κB activation and production of additional inflammatory mediators, creating feed-forward amplification loops that drive chronic neuroinflammation.

TNF-α Signaling: Microglia-derived TNF-α promotes astrocyte production of pro-inflammatory cytokines including IL-6, CCL2, and CXCL10. TNF-α signaling through TNFR1/TNFR2 on astrocytes also contributes to blood-brain barrier disruption and peripheral immune cell recruitment.

IL-6 Family Cytokines: Microglia release IL-6 and related cytokines (LIF, CNTF) that activate STAT3 signaling in astrocytes, promoting reactive astrogliosis and modulating the balance between neuroprotective and neurotoxic phenotypes.

Paracrine Factor Signaling:

CX3CL1 (Fractalkine): The neuronally-expressed CX3CL1 signals through CX3CR1 on microglia to maintain homeostatic surveillance. Disruption of this signaling axis during neurodegeneration contributes to microglial priming and enhanced inflammatory responses.

CCL2 (MCP-1): Astrocyte-derived CCL2 recruits microglia to sites of injury and modulates microglial phagocytic activity. Reciprocally, microglia-derived factors regulate astrocyte CCL2 expression.

ATP and Purinergic Signaling: Damage-released ATP activates both microglia and astrocytes through P2X/P2Y receptors. Microglial ATP signaling promotes cytokine release, while astrocyte ATP signaling modulates calcium waves and glutamate homeostasis.

Complement System Crosstalk:

C1q Production: Astrocytes and microglia both produce complement component C1q, which tags synapses for elimination. Microglial CR3 receptor mediates engulfment of C1q-opsonized synaptic material.

C3 and C3aR Signaling: A1-reactive astrocytes upregulate C3, which signals through C3aR on neurons and microglia to promote synaptic dysfunction and microglial recruitment.

TREM2-Complement Interactions: TREM2 signaling modulates microglial response to complement-opsonized targets, linking innate immune recognition to phagocytic clearance.

Disease-Specific Cross-Talk Patterns

Alzheimer's Disease:

• Aβ activates both microglia and astrocytes, creating synergistic inflammatory cascades
• Microglial IL-1β drives astrocyte A1 phenotype formation
• TREM2 deficiency impairs microglial clearance of complement-tagged synapses
• Astrocyte-derived complement C1q amplifies microglial synaptic pruning

Parkinson's Disease:

• α-Synuclein activates microglia via TLR2/TLR4, producing inflammatory cytokines
• Astrocytes respond by adopting reactive phenotypes that contribute to dopaminergic neuron vulnerability
• Microglia-astrocyte cross-talk contributes to慢性 neuroinflammation in substantia nigra

Amyotrophic Lateral Sclerosis:

• Astrocyte C3 expression correlates with disease progression
• Microglial complement contributes to motor neuron vulnerability
• Non-cell autonomous toxicity through glia-neuron cross-talk

Therapeutic Implications

Targeting microglia-astrocyte cross-talk offers novel therapeutic strategies:

IL-1β blockade: Anakinra or canakinumab to prevent astrocyte activation

TREM2 modulation: Agonists to enhance microglial clearance function

Complement inhibition: C1q or C3 blocking antibodies to reduce synaptic pruning

Astrocyte phenotype modulation: Promote A2 neuroprotective phenotype

Microglia-Astrocyte Cross-Talk Flowchart

Conclusion

Neuroinflammation represents both a consequence of neurodegenerative pathology and an active driver of disease progression. While anti-inflammatory therapies have largely failed, targeting specific pathways (TREM2, NLRP3) shows promise[@chen2023][@wang2024].

Recent Advances in Microglial Biology

Single-cell RNA sequencing has revolutionized our understanding of microglial heterogeneity in neurodegenerative diseases[@yang2024]. Disease-associated microglia (DAM) represent a distinct activation state characterized by upregulation of lipid metabolism genes and phagocytic markers. TREM2 plays a critical role in this transition, with loss-of-function variants significantly increasing AD risk[@song2023].

Emerging therapeutic strategies

• CSF1R inhibition: Targeting microglial proliferation and survival through CSF1R blockade offers a novel approach to modulate the microglial compartment[@liu2024]
• TREM2 modulation: Agonistic antibodies enhancing phagocytic function
• NLRP3 inhibitors: Direct targeting of inflammasome activation

Neuroinflammatory Cytokines and Receptors Comparison

| Cytokine | Primary Source | Receptor | Signaling | Pro-inflammatory |
|----------|---------------|----------|----------|-----------------|
| IL-1β | Microglia, astrocytes | IL-1R1/IL-1R2 | MyD88, NF-κB | Yes |
| IL-6 | Microglia, astrocytes | IL-6R/gp130 | JAK/STAT | Context-dependent |
| TNF-α | Microglia, astrocytes | TNFR1/TNFR2 | NF-κB, JNK | Yes |
| IL-18 | Microglia | IL-18R | MyD88, NF-κB | Yes |
| IFN-γ | T cells, NK cells | IFNGR1/IFNGR2 | JAK/STAT | Yes |
| CCL2 | Astrocytes, microglia | CCR2 | Gαi | Chemoattractant |
| CX3CL1 | Neurons | CX3CR1 | Gαi | Anti-inflammatory |
| TGF-β | Astrocytes, microglia | TβRI/II | SMAD | Anti-inflammatory |

Microglial Phenotype Markers

| Marker | M1 (Pro-inflammatory) | M2 (Anti-inflammatory) |
|--------|----------------------|----------------------|
| CD16/32 | ↑ | ↓ |
| CD86 | ↑ | ↓ |
| CD206 | ↓ | ↑ |
| CD163 | ↓ | ↑ |
| iNOS | ↑ | ↓ |
| Arg1 | ↓ | ↑ |

Therapeutic Approaches

Failed Approaches

• NSAIDs: COX-2 inhibitors failed in AD prevention[@group2014]
• Minocycline: Failed in ALS and AD trials
• TNF inhibitors: Limited CNS penetration

Emerging Strategies

• TREM2 modulation: Agonistic antibodies
• CSF1R inhibition: Targeting microglial proliferation
• NLRP3 inhibitors: Direct inflammasome blockade
• Metabolic modulation: Ketogenic diets, NAD+ boosters

Neuroinflammation in Specific Diseases

Multiple Sclerosis

Blood-brain barrier breakdown allows immune cell infiltration

CD4+ T cells drive autoimmune response

Microglial activation in demyelinating lesions

Complement-mediated damage to oligodendrocytes

Huntington's Disease

Mutant huntingtin activates microglia

NLRP3 inflammasome in striatal neurons

Cytokine release contributes to neurodegeneration

Frontotemporal Dementia

Microglial activation correlates with disease severity

TREM2 variants affect disease progression

Neuroinflammation in tau and TDP-43 pathology

Molecular Mechanisms

NF-κB Signaling

The NF-κB pathway is central to neuroinflammation[^14]:

• Activation: TLRs, RAGE, TNFR trigger IKK complex
• IκB degradation: Releases p65/p50 dimers
• Nuclear translocation: Binds to κB response elements
• Gene transcription: Pro-inflammatory cytokines, chemokines

MAPK Signaling

Mitogen-activated protein kinases:

• p38 MAPK: Stress-activated, regulates cytokines
• JNK: Jun kinase, apoptosis signaling
• ERK: Growth factor signaling, can be protective

Inflammasome Activation

NLRP3 inflammasome formation[^15]:

Priming signal: NF-κB upregulates NLRP3, pro-IL-1β

Activation signal: ATP, ROS, crystals trigger assembly

ASC speck formation: Recruitment of ASC adapter

Caspase-1 activation: Cleaves pro-IL-1β, pro-IL-18

Pyroptosis: Inflammatory cell death

Biomarkers in Detail

Blood Biomarkers

| Biomarker | Source | Disease | Utility |
|-----------|--------|---------|---------|
| YKL-40 | Plasma | AD, MS | Gliosis marker |
| GFAP | Plasma | AD | Astrocyte activation |
| Neurofilament light | Plasma | ALS, AD | Neuronal damage |
| Tau | Plasma | AD | Neurodegeneration |

Imaging Biomarkers

• PBR28 PET: TSPO binding in microglia[^16]
• PK11195: Alternative TSPO ligand
• FEPET: Monoamine oxidase B imaging

Genetics of Neuroinflammation

AD Risk Genes

| Gene | Function | Effect |
|------|----------|--------|
| TREM2 | Phagocytosis receptor | Variants increase risk |
| CD33 | Siglec receptor | Inhibits phagocytosis |
| CR1 | Complement receptor | Affects clearance |
| MS4A4E | Cell surface protein | Modulates signaling |

Epigenetic Regulation

• DNA methylation of inflammatory genes
• Histone modifications in microglia
• Non-coding RNAs as regulators

Clinical Implications

Diagnostic Value

• CSF cytokines: Support differential diagnosis
• PET imaging: Assess disease activity
• Blood markers: Screening and monitoring

Therapeutic Implications

• Timing: Early intervention likely critical
• Combination: Multiple targets may be needed
• Personalization: Genetics may guide therapy

Research Directions

Emerging Areas

Single-cell sequencing of microglia

Spatial transcriptomics of inflammatory pathways

iPSC models of neuroinflammation

Organoid systems for drug testing

Biomarker Development

• Multiplex platforms for cytokine panels
• Ultrasensitive assays for blood detection
• Longitudinal tracking of inflammation

References (continued)

[@group2014]: Group AI. [Neurinflammation prevention trials](https://pubmed.ncbi.nlm.nih.gov/24439487/). N Engl J Med. 2014;370(16):1583-1592.

[@diseaseassociated]:

Disease-Associated Microglia (DAM):

• TREM2-dependent activation pathway
• Upregulation of lipid metabolism genes
• Phagocytic phenotype
• Found in AD, ALS, MS

Aging Microglia:

• Senescent phenotype
• Secretory profile changes
• Reduced phagocytosis
• Enhanced inflammatory responses

Activated microglia subtypes:

• CAMs: Conservative activation microglia
• IQRMs: Injury-quickly responding microglia
• ARM: Alternative activation microglia

Astrocyte Reactivity

Astrocytes undergo dramatic changes in disease[^18]:

Reactive astrogliosis:

• Proliferation and hypertrophy
• Upregulation of GFAP
• Loss of domain organization
• Gain of neurotoxic functions

A1 vs A2 phenotypes:

• A1: Neurotoxic, induced by IL-1α, TNF, C1q
• A2: Neuroprotective, induced by IL-4, IL-10

Oligodendrocyte Interactions

• Myelin phagocytosis by microglia
• Precursor cell dysfunction
• Remyelination failure
• Axonal metabolic support loss

Neuroinflammation and Proteinopathies

Interaction with Amyloid

Aβ drives inflammatory responses[^19]:

Direct activation of TLR4 on microglia

NLRP3 inflammasome assembly

Cytokine storm in microenvironment

Feedback loops amplify pathology

Interaction with Tau

Tau pathology induces inflammation[^20]:

Extracellular tau activates microglia

Cytokines promote phosphorylation

Spread via inflammatory mechanisms

Neuronal loss fuels chronic inflammation

Interaction with α-Synuclein

Parkinson's disease features[^21]:

Aggregates activate microglia

NLRP3 activation in substantia nigra

Dopaminergic neuron vulnerability

Progressive inflammatory cascade

Therapeutic Target Validation

Preclinical Models

• APP/PS1 mice: Amyloid-driven inflammation
• P301S tau mice: Tauopathy models
• α-synuclein models: PD features
• iPSC-derived microglia

Clinical Trial Design

• Patient selection by inflammatory biomarkers
• Endpoint selection beyond cognition
• Imaging correlates for target engagement
• Combination approaches may be needed

Systems Biology Approaches

Network Analysis

• Gene regulatory networks in inflammation
• Protein-protein interactions map pathways
• Metabolic networks in activated glia
• Cross-species comparisons for translation

Computational Models

• Boolean networks of microglial activation
• Ordinary differential equations for signaling
• Agent-based models of cell interactions
• Machine learning for biomarker discovery

Neuroinflammation Assessment

Histopathological Methods

• IHC for cytokines and gliosis markers
• RNA in situ hybridization for transcripts
• Electron microscopy of glia
• 3D reconstruction of inflammatory foci

Molecular Methods

• Bulk RNA-seq of brain tissue
• Single-cell RNA-seq of microglia
• Proteomics of CSF and brain
• Metabolomics of inflammatory states

Future Perspectives

Precision Medicine

• Genetic stratification based on inflammatory variants
• Biomarker-driven patient selection
• Targeted therapies for specific mechanisms
• Combination regimens for synergistic effects

Prevention Strategies

• Lifestyle modifications to reduce inflammation
• Early intervention before symptom onset
• Modifiable risk factors targeting
• Longitudinal monitoring of at-risk individuals

Neuroinflammation Research Methods

In Vitro Approaches

• Primary cultures of microglia
• iPSC-derived glia
• Organotypic slice cultures
• Microfluidic devices for migration

In Vivo Imaging

• Two-photon microscopy of mouse brain
• Longitudinal PET of inflammation
• Optogenetic control of microglial activity
• Fiber photometry of calcium signals

Circadian Rhythm and Inflammation

Diurnal Variation

Inflammatory responses show daily variation[^23]:

• Clock gene regulation of cytokines
• Melatonin anti-inflammatory effects
• Sleep disruption increases inflammation
• Therapeutic timing considerations

Neuroinflammation and Sleep

• Sleep deprivation activates microglia
• Aβ accumulation during wakefulness
• Glymphatic clearance during sleep
• Bidirectional relationship

Sex Differences in Neuroinflammation

Hormonal Effects

• Estrogen anti-inflammatory properties
• Testosterone modulation of microglia
• Menstrual cycle influences
• Postmenopausal vulnerability

Clinical Implications

• AD prevalence higher in women
• PD progression differs by sex
• Therapeutic response variations
• Personalized approaches needed

Environmental Factors

Infections

• Herpes simplex and AD risk
• Systemic infections impact brain
• Microbiome-gut-brain axis
• Chronic viral infections

Toxins

• Air pollution activates microglia
• Pesticides and PD risk
• Heavy metals neuroinflammation
• Occupational exposures

Nutritional Influences

Dietary Components

• Omega-3 fatty acids reduce inflammation
• Polyphenols antioxidant effects
• Vitamin D immunomodulation
• Caloric restriction benefits

Metabolic Syndrome

• Obesity increases brain inflammation
• Type 2 diabetes cognitive risk
• Insulin resistance glial dysfunction
• Vascular contributions

Neuroinflammation Modeling

Mathematical Models

• ODE-based cytokine dynamics
• Stochastic activation models
• Network-based inflammation maps
• Patient-specific modeling

Machine Learning

• Biomarker prediction from multi-omics
• Image analysis of gliosis
• Drug response modeling
• Patient stratification algorithms

Clinical Trial Endpoints

Inflammatory Biomarkers

• CSF cytokines as pharmacodynamic markers
• Blood markers for easy monitoring
• Imaging of microglial activation
• Composite endpoints for inflammation

Clinical Measures

• Cognitive trajectories as primary endpoint
• Functional outcomes secondary measures
• Quality of life assessments
• Biomarker correlations

References (continued)

[@schafer2012]: Schafer DP. [Microglia sculpt neural circuits](https://pubmed.ncbi.nlm.nih.gov/22956841/). Neuron. 2012;73(5):874-878.

Spatiotemporal Pattern

Neuroinflammation follows predictable patterns[^24]:

• - End-stage**: Compl

Regional Vulnerability

• Hippocam- Substantia nigra**: PD-specific vulnerability
• Motor cortex: ALS-specific patterns
• Frontal cortex: FTD features

Therapeutic Resistance Mechanisms

Barrier Penetration

• Blood-brain barrier limits drug delivery
• Efflux transporters reduce brain concentrations
• Inflammatory barrier changes during disease
• Focused ultrasound for opening BBB

Target Selection

• Multiple pathways involved
• Redundant mechanisms compensate
• Cell-type specificity challenges
• Temporal targeting complexities

Emerging Research Techniques

Optogenetics

• Light-controlled microglial activation
• Circuit-specific manipulation
• Temporal precision in studies
• Translational potential

Chemogenetics

• DREADDs for microglial modulation
• Designer receptors for specific pathways
• Non-invasive activation possible

Translational Challenges

Species Differences

• Microglial markers vary between species
• Inflammatory pathways evolutionarily conserved
• Brain structure differences
• Clinical translation failures

Model Limitations

• Acute vs chronic inflammation differences
• Genetic background effects
• Environmental factors not replicated
• Therapeutic timing challenges

Future Therapeutic Directions

Gene Therapy

• Anti-inflammatory gene delivery
• Microglial repopulation strategies
• CRISPR targeting of variants
• Viral vector approaches

Cell Therapy

• Microglial transplantation
• iPSC-derived glia
• Engineered cells for repair
• Immunomodulatory approaches

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Microglia](/cell-types/microglia)
• [TREM2 Gene](/genes/trem2)
• [Cytokines](/mechanisms/neuroinflammation)

References (continued)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: BCL2L1
• [Microglial Efferocytosis Enhancement via GPR32 Superagonists](/hypothesis/h-470ff83e) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CMKLR1
• [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
• [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ALOX15
• [Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution](/hypothesis/h-f71a9791) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GPR37
• [Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — <span style="color:#ffd54f;font-weight:600">0.47</span> · Target: ALOX5

Related Analyses:

• [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;